 NEW YORK, June 28, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in July: June 30-July 3: The International Federation of Psoriasis Associations 6th World Psoriasis Psoriatic Arthritis Conference 2021. Dr. Thomas M Polasek, Clinical Pharmacology Registrar, Royal Adelaide Hospital, Australia, will present the first clinical experience with IMU-935, an orally available, selective inverse agonist of RORγt. 